Journal
METABOLITES
Volume 11, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/metabo11120812
Keywords
metabolomics; autoimmune disease; pharmacometabolomics
Categories
Ask authors/readers for more resources
This paper outlines recent advances in metabolomics research of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, describing newly discovered biomarkers and metabolic mechanism studies for these diseases. It also presents studies elucidating the metabolic mechanisms underlying these diseases and summarizes biomarker studies aimed at predicting personalized medicine and drug response.
The metabolomics approach represents the last downstream phenotype and is widely used in clinical studies and drug discovery. In this paper, we outline recent advances in the metabolomics research of autoimmune diseases (ADs) such as rheumatoid arthritis (RA), multiple sclerosis (MuS), and systemic lupus erythematosus (SLE). The newly discovered biomarkers and the metabolic mechanism studies for these ADs are described here. In addition, studies elucidating the metabolic mechanisms underlying these ADs are presented. Metabolomics has the potential to contribute to pharmacotherapy personalization; thus, we summarize the biomarker studies performed to predict the personalization of medicine and drug response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available